Key result
Aortic radiation linked to ~59% greater CAD risk per 5 Gy in childhood cancer survivors.
Why the study?
Whole-heart radiation dose may mask heterogeneous cardiac substructure exposure, limiting precision in survivorship surveillance and modern radiotherapy planning for childhood cancer survivors.
Does cardiac substructure-specific radiation dose predict late cardiovascular events in childhood cancer survivors?
Cohort (n=25,481)
Does cardiac substructure-specific radiation dose predict late cardiovascular events in childhood cancer survivors?
Effect estimate: HR 1.59 (95% CI 1.14-2.21)
Specific cardiac substructure radiation doses, particularly to the LAD and aorta, are strong predictors of late cardiovascular events in childhood cancer survivors, enabling targeted 20-year risk thresholds for survivorship surveillance.
May inform substructure-specific CAD/CHF risk thresholds in childhood cancer survivors; leaves open prospective validation of dose constraints.
12123 Background: Radiation-associated cardiovascular disease (CVD) remains a major late toxicity in childhood cancer survivors. Whole-heart dose may mask heterogeneous substructure exposure, limiting precision in survivorship surveillance and modern radiotherapy planning. Methods: Using the Childhood Cancer Survivor Study (CCSS) open-access cardiac substructure dosimetry dataset (12 mean-dose structures; Gy), we modeled time from cancer diagnosis to CAD, CHF, valvular disease, and arrhythmia with elastic-net Cox (α=0.5; 10-fold CV). Bootstrap stability selection (200 resamples) quantified reproducible substructure predictors; “core” structures were defined by selection frequency ≥0.80. Parsimonious Cox models were fit using core structures (dose scaled per 5 Gy) and adjusted for sex, race, age at diagnosis, anthropometric category, and smoking. Model discrimination was assessed using the concordance index (C-index). Model-based predicted 20-year absolute risks were used to estimate dose thresholds for clinically interpretable risk targets (reference profile: median covariates; modal factor levels). Results: Among 25,481 survivors, events occurred for CAD (n=475), CHF (n=544), valvular disease (n=131), and arrhythmia (n=181). LAD and aorta emerged as reproducible, endpoint-specific predictors: LAD was core across CAD/CHF/valvular outcomes; aorta and LMCA were core for CAD/valvular; pericardium was core for CAD/CHF. In adjusted core models, aortic dose was associated with CAD (HR 1.59 per 5 Gy; 95% CI 1.14–2.21; C-index 0.796) and valvular disease (HR 1.96; 95% CI 1.15–3.32; C-index 0.773). LAD dose was associated with CAD (HR 1.26; 95% CI 1.05–1.53; C-index 0.796) and CHF (HR 1.23; 95% CI 1.02–1.47; C-index 0.818). Absolute risk translation identified interpretable thresholds: predicted 20-year CAD risk crossed ~1% at 13 Gy mean aortic dose and ~2% at 20 Gy; CAD risk crossed ~1% at 24 Gy mean LAD dose. Predicted 20-year CHF risk crossed ~0.5% at 21 Gy mean LAD dose. Predicted 20-year valvular risk crossed ~1% at 23 Gy mean aortic dose. Conclusions: Substructure-specific dosimetry yields reproducible radiation “signatures,” with LAD and aorta dose consistently linked to late CVD. These dose–risk thresholds provide actionable benchmarks for risk-stratified survivorship surveillance and may inform substructure-sparing dose constraints in contemporary radiotherapy planning moving beyond whole-heart dose to endpoint-specific substructure constraints. Substructure-specific dose thresholds for 20-year cardiovascular risk. Outcome Core Substructure HR per 5 Gy (95% CI) 20-Year Risk Target Dose Threshold (Gy) CAD Aorta 1.59 (1.14–2.21) 1% 13 CAD Aorta 1.59 (1.14–2.21) 2% 20 CAD LAD 1.26 (1.05–1.53) 1% 24 CHF LAD 1.23 (1.02–1.47) 0.5% 21 Valvular Aorta 1.96 (1.15–3.32) 1% 23
No takes yet. Share an insight, caveat, or question.
Pamreddy et al. (2026) conducted a cohort in Childhood cancer survivors (n=25,481). Cardiac substructure radiation dose was evaluated on Time from cancer diagnosis to CAD, CHF, valvular disease, and arrhythmia (HR 1.59, 95% CI 1.14-2.21). Aortic radiation dose was associated with increased CAD risk (HR 1.59 per 5 Gy; 95% CI 1.14–2.21), while LAD dose was associated with CAD and CHF in childhood cancer survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: